Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
Imperial College Healthcare NHS Trust
St Mary's Hospital, Praed Street
London
W2 1NY
UK
E-mail: gemma.fahey@nhs.net
NUTS: UKI33
Internet address(es)
Main address: https://www.imperial.nhs.uk
Address of the buyer profile: https://www.imperial.nhs.uk
I.4) Type of the contracting authority
Other: NHS
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Provision of HTLV Pathology Services
Reference number: C474616
II.1.2) Main CPV code
85111800
II.1.3) Type of contract
Services
II.1.4) Short description
The HTLV pathology service will support the diagnosis, prognosis and<br/>monitoring of:<br/><br/>• HTLV infection with the provision of assays to detect, type and<br/>quantify HTLV infection, and<br/>• HTLV associated diseases particularly detection of high risk for or<br/>early disease and the monitoring of interventions to inform disease<br/>management.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
376 268.00
GBP
II.2) Description
II.2.2) Additional CPV code(s)
85111800
II.2.3) Place of performance
NUTS code:
UKI
II.2.4) Description of the procurement
The HTLV pathology service will support the diagnosis, prognosis and<br/>monitoring of:<br/><br/>• HTLV infection with the provision of assays to detect, type and<br/>quantify HTLV infection, and<br/>• HTLV associated diseases particularly detection of high risk for or<br/>early disease and the monitoring of interventions to inform disease<br/>management.<br/>An award has been made under PSR direct award process A.<br/>Total contract value of £376,268.00 between 05/10/26-04/10/28.
II.2.5) Award criteria
Quality criterion: No alternative supplier
/ Weighting: 100
Price
/ Weighting:
0
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Award of a contract without prior publication of a call for competition
Justification for selected award procedure:
The procurement falls outside the scope of application of the Directive
Explanation
The Molecular Diagnostic Unit (MDU) at Imperial College London <br/>is the only capable provider. <br/>The MDU provides NCHR with bespoke diagnostic assays that <br/>have been developed and validated for NCHR by the Section of <br/>Virology for patient benefit. These assays are essential for the <br/>assessment of HTLV-1-associated disease risk and are used to <br/>determine the frequency of clinic visits, (optimizing the use of <br/>clinical services), detect and allow early treatment of HTLV-1<br/>associated disease and monitor treatment responses. <br/>Continued provision of these assays by the MDU is justified on <br/>the following grounds: <br/>• The assays were developed by the MDU as part of the <br/>HTLV National Service provision. <br/>• The assays are either only available in the UK at the <br/>MDU (HTLV proviral quantification) or are only available <br/>in the World at the MDU (HTLV Clonality Assay). <br/>• The assays would not have been developed without the <br/>partnership between ICHNT/ICL. <br/>• Samples sent for proviral load quantification are stored <br/>viably to allow access to cells for the HTLV clonality <br/>Assay later (once the proviral load is known). <br/>• The MDU is uniquely placed to provide interpretation and <br/>clinical support. <br/>• All patients in England receive the same standard of care, which <br/>is world leading. The Direct Award Process A justification is <br/>based on the provider’s specialist HTLV assay capability, <br/>validated methodology, continuity of stored viable samples, <br/>UKAS-accredited laboratory provision, and clinical integration <br/>with the National Centre for Human Retrovirology. (Supporting <br/>evidence available and retained to demonstrate that there is no <br/>realistic alternative provider for the full requirement)
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
No
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
24/09/2026
V.2.2) Information about tenders
Number of tenders received: 1
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Molecular Diagnostic Unit, Imperial College London
Faculty of Medicine Room I.2.03 2nd Floor Lift Bank D Chelsea & Westminster Hospital 369 Fulham Road London
London
SW10 9NH
UK
E-mail: anjna.badhan@imperial.ac.uk
NUTS: UKI
The contractor is an SME:
Yes
V.2.4) Information on value of the contract/lot (excluding VAT)
Initial estimated total value of the contract/lot:
Total value of the contract/lot:
: 376 268.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.'<br/>Decision makers details are followed, no conflict of interests were declared:<br/>Gemma Fahey -Senior Sourcing Manager, Simon Rooney - Senior Sourcing Manager, Nicola Sinnett - Head <br/>of Category – Diagnostics and Pathology, Keith Hinchcliffe - Category Director, Gillian Stevens - Operational Lead, Patricia Reyes - Director of Operations, Alexandra Bowyer - Finance Business Partner and Jazz Thind - Chief Financial Officer.
VI.4) Procedures for review
VI.4.1) Review body
NHS England
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
UK
E-mail: england.commercialqueries@nhs.net
Internet address(es)
URL: https://www.england.nhs.uk/
VI.5) Date of dispatch of this notice
14/10/2026